Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells

Detalhes bibliográficos
Autor(a) principal: Ana Delia Pinzón García
Data de Publicação: 2021
Outros Autores: Rubén Dario Sinisterra Millán, María Esperanza Cortés Segura, Fredy Mesa, Sandra Ramírez-Clavijo
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFMG
Texto Completo: https://doi.org/10.7717/peerj.12124
http://hdl.handle.net/1843/61926
https://orcid.org/0000-0002-8876-4907
https://orcid.org/0000-0001-7656-1849
https://orcid.org/0000-0002-0560-8491
Resumo: Breast cancer is the second leading cause of death in women, and tamoxifen citrate (TMX) is accepted widely for the treatment of hormone receptor–positive breast cancers. Several local drug-delivery systems, including nanofibers, have been developed for antitumor treatment. Nanofibers are biomaterials that mimic the natural extracellular matrix, and they have been used as controlled release devices because they enable highly efficient drug loading. The purpose of the present study was to develop polycaprolactone (PCL) nanofibers incorporating TMX for use in the treatment of breast tumors. Pristine PCL and PCL-TMX nanofibers were produced by electrospinning and characterized physiochemically using different techniques. In addition, an in vitro study of TMX release from the nanofibers was performed. The PCL-TMX nanofibers showed sustained TMX release up to 14 h, releasing 100% of the TMX. The Resazurin reduction assay was used to evaluate the TMX cytotoxicity on MCF-7 breast cancer cell line and PBMCs human. The PCL-TMX nanofiber was cytotoxic toPBMCs and MCF-7. Based on these results, the PCL-TMX nanofibers developed have potential as an alternative for local chronic TMX use for breast cancer treatment, however tissue tests must be done.
id UFMG_72d345385d0aee9173140601dddc0a4c
oai_identifier_str oai:repositorio.ufmg.br:1843/61926
network_acronym_str UFMG
network_name_str Repositório Institucional da UFMG
repository_id_str
spelling Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cellsTamoxifen citrateNanofibersPolycaprolactoneBreast CancerBioquímicaBioengenhariaBiotecnologia farmacêuticaMamas - CâncerCâncer - TratamentoReceptores hormonaisTecnologia de liberação controladaBreast cancer is the second leading cause of death in women, and tamoxifen citrate (TMX) is accepted widely for the treatment of hormone receptor–positive breast cancers. Several local drug-delivery systems, including nanofibers, have been developed for antitumor treatment. Nanofibers are biomaterials that mimic the natural extracellular matrix, and they have been used as controlled release devices because they enable highly efficient drug loading. The purpose of the present study was to develop polycaprolactone (PCL) nanofibers incorporating TMX for use in the treatment of breast tumors. Pristine PCL and PCL-TMX nanofibers were produced by electrospinning and characterized physiochemically using different techniques. In addition, an in vitro study of TMX release from the nanofibers was performed. The PCL-TMX nanofibers showed sustained TMX release up to 14 h, releasing 100% of the TMX. The Resazurin reduction assay was used to evaluate the TMX cytotoxicity on MCF-7 breast cancer cell line and PBMCs human. The PCL-TMX nanofiber was cytotoxic toPBMCs and MCF-7. Based on these results, the PCL-TMX nanofibers developed have potential as an alternative for local chronic TMX use for breast cancer treatment, however tissue tests must be done.CNPq - Conselho Nacional de Desenvolvimento Científico e TecnológicoFAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas GeraisCAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível SuperiorUniversidade Federal de Minas GeraisBrasilFAO - DEPARTAMENTO DE ODONTOLOGIA RESTAURADORAICX - DEPARTAMENTO DE QUÍMICAUFMG2023-12-12T18:45:53Z2023-12-12T18:45:53Z2021info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlepdfapplication/pdfhttps://doi.org/10.7717/peerj.121242167-8359http://hdl.handle.net/1843/61926https://orcid.org/0000-0002-8876-4907https://orcid.org/0000-0001-7656-1849https://orcid.org/0000-0002-0560-8491engPeerJAna Delia Pinzón GarcíaRubén Dario Sinisterra MillánMaría Esperanza Cortés SeguraFredy MesaSandra Ramírez-Clavijoinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFMGinstname:Universidade Federal de Minas Gerais (UFMG)instacron:UFMG2023-12-12T18:45:55Zoai:repositorio.ufmg.br:1843/61926Repositório InstitucionalPUBhttps://repositorio.ufmg.br/oairepositorio@ufmg.bropendoar:2023-12-12T18:45:55Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)false
dc.title.none.fl_str_mv Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells
title Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells
spellingShingle Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells
Ana Delia Pinzón García
Tamoxifen citrate
Nanofibers
Polycaprolactone
Breast Cancer
Bioquímica
Bioengenharia
Biotecnologia farmacêutica
Mamas - Câncer
Câncer - Tratamento
Receptores hormonais
Tecnologia de liberação controlada
title_short Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells
title_full Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells
title_fullStr Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells
title_full_unstemmed Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells
title_sort Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells
author Ana Delia Pinzón García
author_facet Ana Delia Pinzón García
Rubén Dario Sinisterra Millán
María Esperanza Cortés Segura
Fredy Mesa
Sandra Ramírez-Clavijo
author_role author
author2 Rubén Dario Sinisterra Millán
María Esperanza Cortés Segura
Fredy Mesa
Sandra Ramírez-Clavijo
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Ana Delia Pinzón García
Rubén Dario Sinisterra Millán
María Esperanza Cortés Segura
Fredy Mesa
Sandra Ramírez-Clavijo
dc.subject.por.fl_str_mv Tamoxifen citrate
Nanofibers
Polycaprolactone
Breast Cancer
Bioquímica
Bioengenharia
Biotecnologia farmacêutica
Mamas - Câncer
Câncer - Tratamento
Receptores hormonais
Tecnologia de liberação controlada
topic Tamoxifen citrate
Nanofibers
Polycaprolactone
Breast Cancer
Bioquímica
Bioengenharia
Biotecnologia farmacêutica
Mamas - Câncer
Câncer - Tratamento
Receptores hormonais
Tecnologia de liberação controlada
description Breast cancer is the second leading cause of death in women, and tamoxifen citrate (TMX) is accepted widely for the treatment of hormone receptor–positive breast cancers. Several local drug-delivery systems, including nanofibers, have been developed for antitumor treatment. Nanofibers are biomaterials that mimic the natural extracellular matrix, and they have been used as controlled release devices because they enable highly efficient drug loading. The purpose of the present study was to develop polycaprolactone (PCL) nanofibers incorporating TMX for use in the treatment of breast tumors. Pristine PCL and PCL-TMX nanofibers were produced by electrospinning and characterized physiochemically using different techniques. In addition, an in vitro study of TMX release from the nanofibers was performed. The PCL-TMX nanofibers showed sustained TMX release up to 14 h, releasing 100% of the TMX. The Resazurin reduction assay was used to evaluate the TMX cytotoxicity on MCF-7 breast cancer cell line and PBMCs human. The PCL-TMX nanofiber was cytotoxic toPBMCs and MCF-7. Based on these results, the PCL-TMX nanofibers developed have potential as an alternative for local chronic TMX use for breast cancer treatment, however tissue tests must be done.
publishDate 2021
dc.date.none.fl_str_mv 2021
2023-12-12T18:45:53Z
2023-12-12T18:45:53Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.7717/peerj.12124
2167-8359
http://hdl.handle.net/1843/61926
https://orcid.org/0000-0002-8876-4907
https://orcid.org/0000-0001-7656-1849
https://orcid.org/0000-0002-0560-8491
url https://doi.org/10.7717/peerj.12124
http://hdl.handle.net/1843/61926
https://orcid.org/0000-0002-8876-4907
https://orcid.org/0000-0001-7656-1849
https://orcid.org/0000-0002-0560-8491
identifier_str_mv 2167-8359
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv PeerJ
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv pdf
application/pdf
dc.publisher.none.fl_str_mv Universidade Federal de Minas Gerais
Brasil
FAO - DEPARTAMENTO DE ODONTOLOGIA RESTAURADORA
ICX - DEPARTAMENTO DE QUÍMICA
UFMG
publisher.none.fl_str_mv Universidade Federal de Minas Gerais
Brasil
FAO - DEPARTAMENTO DE ODONTOLOGIA RESTAURADORA
ICX - DEPARTAMENTO DE QUÍMICA
UFMG
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFMG
instname:Universidade Federal de Minas Gerais (UFMG)
instacron:UFMG
instname_str Universidade Federal de Minas Gerais (UFMG)
instacron_str UFMG
institution UFMG
reponame_str Repositório Institucional da UFMG
collection Repositório Institucional da UFMG
repository.name.fl_str_mv Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)
repository.mail.fl_str_mv repositorio@ufmg.br
_version_ 1816829769777414144